Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Seattle Genetics And Genmab Partner Again On Anti-Cancer ADC

Executive Summary

MabVax to provide antibody-targeting technology to Memorial Sloan-Kettering, which could yield CAR-T therapeutic candidates for which Juno Therapeutics will hold an exclusive option. Mylan acquires injectable anticoagulant Arixtra from Aspen for $300 million, while Asterias will work with Cancer Research UK on non-small cell lung cancer program.

You may also be interested in...

Deal Watch: Infinity Scores With AbbVie Deal, AbbVie Tries New Angle With Calico

Infinity gains street cred with AbbVie partnership on duvelisib, while AbbVie also branches out into aging disease by obtaining a stake in Google’s Calico; Palatin and Gedeon Richter pair up on female sexual dysfunction; and AstraZeneca finds an oncology discovery engine in Redx.

Spinal Cord Injury Product Makes Progress As Asterias Picks Up Where Geron Left Off

New endpoint guidelines – and matching grant funding from the California Institute for Regenerative Medicine – enhance possibility of demonstrating functional improvement in the Phase I/IIa trial of the stem-cell therapeutic.

AstraZeneca, Pfizer, U.K. Charity’s Joint Lung Cancer Trial Aims To Make Tumor Genetic Testing Routine

A pioneering approach to trialing targeted medicines in late-stage NSCLC is being launched throughout Britain, giving researchers unprecedented access to libraries of drugs developed by AstraZeneca and Pfizer, allowing several to be tested at the same time within one trial.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts